364 related articles for article (PubMed ID: 27379555)
1. Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States.
Gharibi Z; Ayvaci MUS; Hahsler M; Giacoma T; Gaston RS; Tanriover B
Transplantation; 2017 Jun; 101(6):1234-1241. PubMed ID: 27379555
[TBL] [Abstract][Full Text] [Related]
2. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Early Steroid Withdrawal in Recipients of Deceased-Donor Expanded Criteria Kidney Transplants in the Era of Induction Therapy.
Hussain SM; Marcus RJ; Ko TY; Nashar K; Thai NL; Sureshkumar KK
Exp Clin Transplant; 2016 Jun; 14(3):287-93. PubMed ID: 27221720
[TBL] [Abstract][Full Text] [Related]
4. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
Tanriover B; Jaikaransingh V; MacConmara MP; Parekh JR; Levea SL; Ariyamuthu VK; Zhang S; Gao A; Ayvaci MUS; Sandikci B; Rajora N; Ahmed V; Lu CY; Mohan S; Vazquez MA
Clin J Am Soc Nephrol; 2016 Sep; 11(9):1650-1661. PubMed ID: 27364616
[TBL] [Abstract][Full Text] [Related]
5. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic analysis of short-course versus standard-course antithymocyte globulin (rabbit) induction therapy in deceased-donor renal transplant recipients.
Marfo K; Akalin E; Wang C; Lu A
Am J Health Syst Pharm; 2011 Dec; 68(23):2276-82. PubMed ID: 22095818
[TBL] [Abstract][Full Text] [Related]
7. Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression.
Sureshkumar KK; Thai NL; Hussain SM; Ko TY; Marcus RJ
Transplantation; 2012 Apr; 93(8):799-805. PubMed ID: 22290269
[TBL] [Abstract][Full Text] [Related]
8. Steroid maintenance in repeat kidney transplantation: influence of induction agents on outcomes.
Sureshkumar KK; Hussain SM; Nashar K; Marcus RJ
Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):741-9. PubMed ID: 24969182
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
10. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients.
Kuo HT; Huang E; Emami S; Pham PT; Wilkinson AH; Danovitch GM; Bunnapradist S
Transplantation; 2012 Mar; 93(5):493-502. PubMed ID: 22306574
[TBL] [Abstract][Full Text] [Related]
11. Low-dose rabbit anti-thymoglobin globulin versus basiliximab for induction therapy in kidney transplantation.
Patel HV; Kute VB; Vanikar AV; Shah PR; Gumber MR; Engineer DP; Trivedi HL
Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):819-22. PubMed ID: 24969194
[TBL] [Abstract][Full Text] [Related]
12. A Cost-effectiveness Analysis of Rabbit Antithymocyte Globulin Versus Antithymocyte Globulin-fresenius as Induction Therapy for Patients With Kidney Transplantation From Donation After Cardiac Death in China.
Xuan D; Chen G; Wang C; Yao X; Yin H; Zhang L; Xuan J; Chen L
Clin Ther; 2018 Oct; 40(10):1741-1751. PubMed ID: 30243768
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes associated with induction regimens among retransplant kidney recipients in the United States.
Schold J; Poggio E; Goldfarb D; Kayler L; Flechner S
Transplantation; 2015 Jun; 99(6):1165-71. PubMed ID: 25606788
[TBL] [Abstract][Full Text] [Related]
15. Influence of maintenance steroids on the outcomes in deceased-donor kidney transplant recipients exposed to prolonged pretransplantation dialysis.
Sureshkumar KK; Hussain SM; Thai NL; Marcus RJ
Transplant Proc; 2013; 45(1):99-101. PubMed ID: 23375281
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.
Hao WJ; Zong HT; Cui YS; Zhang Y
Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab induction in deceased donor kidney transplantation.
Huang E; Cho YW; Hayashi R; Bunnapradist S
Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
[TBL] [Abstract][Full Text] [Related]
18. Induction Therapy, Rejection, and Graft Outcomes in Pediatric and Adolescent Kidney Transplant Recipients.
Mincham CM; Wong G; Teixeira-Pinto A; Kennedy S; Alexander S; Larkins N; Lim WH
Transplantation; 2017 Sep; 101(9):2146-2151. PubMed ID: 28832451
[TBL] [Abstract][Full Text] [Related]
19. Depleting Antibody Induction and Kidney Transplant Outcomes: A Paired Kidney Analysis.
Sampaio MS; Chopra B; Sureshkumar KK
Transplantation; 2017 Oct; 101(10):2527-2535. PubMed ID: 28475563
[TBL] [Abstract][Full Text] [Related]
20. Polyclonal versus monoclonal induction therapy in a calcineurin inhibitor-free immunosuppressive therapy in renal transplantation: a comparison of efficacy and costs.
Sánchez-Escuredo A; Alsina A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofan F; Fernandez E; Campistol JM; Oppenheimer F
Transplant Proc; 2015; 47(1):45-9. PubMed ID: 25645767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
